Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

73 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
AURIEL-PsO: a randomized, double-blind phase III equivalence trial to demonstrate the clinical similarity of the proposed biosimilar MSB11022 to reference adalimumab in patients with moderate-to-severe chronic plaque-type psoriasis.
Hercogová J, Papp KA, Chyrok V, Ullmann M, Vlachos P, Edwards CJ. Hercogová J, et al. Among authors: ullmann m. Br J Dermatol. 2020 Feb;182(2):316-326. doi: 10.1111/bjd.18220. Epub 2019 Sep 26. Br J Dermatol. 2020. PMID: 31206593 Free PMC article. Clinical Trial.
Immunogenicity and safety of a proposed pegfilgrastim biosimilar MSB11455 versus the reference pegfilgrastim Neulasta® in healthy subjects: A randomized, double-blind trial.
Wynne C, Schwabe C, Vincent E, Schueler A, Ryding J, Ullmann M, Ghori V, Kanceva R, Stahl M. Wynne C, et al. Among authors: ullmann m. Pharmacol Res Perspect. 2020 Apr;8(2):e00578. doi: 10.1002/prp2.578. Pharmacol Res Perspect. 2020. PMID: 32333641 Free PMC article. Clinical Trial.
Pharmacokinetics and Pharmacodynamics of a Proposed Pegfilgrastim Biosimilar MSB11455 Versus the Reference Pegfilgrastim Neulasta in Healthy Subjects: A Randomized, Double-blind Trial.
Lickliter J, Kanceva R, Vincent E, Schueler A, Harrison-Moench E, Yue CS, Stahl M, Ullmann M, Ghori V, Griffin P. Lickliter J, et al. Among authors: ullmann m. Clin Ther. 2020 Aug;42(8):1508-1518.e1. doi: 10.1016/j.clinthera.2020.05.020. Epub 2020 Jul 11. Clin Ther. 2020. PMID: 32660769 Free article. Clinical Trial.
Pharmacokinetics and pharmacodynamics of a proposed tocilizumab biosimilar MSB11456 versus both the US-licensed and EU-approved products: a randomized, double-blind trial.
Schwabe C, Illes A, Ullmann M, Ghori V, Vincent E, Petit-Frere C, Monnet J, Racault AS, Wynne C. Schwabe C, et al. Among authors: ullmann m. Expert Rev Clin Immunol. 2022 May;18(5):533-543. doi: 10.1080/1744666X.2022.2060204. Epub 2022 Apr 10. Expert Rev Clin Immunol. 2022. PMID: 35354411 Clinical Trial.
Pharmacokinetics of a proposed tocilizumab biosimilar (MSB11456) versus US-licensed tocilizumab: results of a randomized, double-blind, single-intravenous dose study in healthy adults.
Tomaszewska-Kiecana M, Ullmann M, Petit-Frere C, Monnet J, Dagres C, Illes A. Tomaszewska-Kiecana M, et al. Among authors: ullmann m. Expert Rev Clin Immunol. 2023 Apr;19(4):439-446. doi: 10.1080/1744666X.2023.2174104. Epub 2023 Feb 13. Expert Rev Clin Immunol. 2023. PMID: 36715299 Clinical Trial.
Pharmacokinetics and tolerability of prefilled syringe and auto-injector presentations of MSB11456: results of a randomized, single-dose study in healthy adults.
Tomaszewska-Kiecana M, Dryja A, Ullmann M, Petit-Frere C, Illes A, Dagres C, Monnet J. Tomaszewska-Kiecana M, et al. Among authors: ullmann m. Expert Rev Clin Immunol. 2023 Apr;19(4):447-455. doi: 10.1080/1744666X.2023.2174970. Epub 2023 Feb 15. Expert Rev Clin Immunol. 2023. PMID: 36789991 Clinical Trial.
Comparison of the efficacy and safety of a proposed biosimilar MSB11456 with tocilizumab reference product in subjects with moderate-to-severe rheumatoid arthritis: results of a randomised double-blind study.
Zubrzycka-Sienkiewicz A, Klama K, Ullmann M, Petit-Frere C, Baker P, Monnet J, Illes A. Zubrzycka-Sienkiewicz A, et al. Among authors: ullmann m. RMD Open. 2024 Feb 5;10(1):e003596. doi: 10.1136/rmdopen-2023-003596. RMD Open. 2024. PMID: 38316489 Free article. Clinical Trial.
73 results